Irene M Ghobrial

Sort by:

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake E. Delmore, Ghayas C. Issa, +21 authors Constantine Mitsiades
Cell
2011

MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC… (More)

Biological properties of extracellular vesicles and their physiological functions

María Yáñez-Mó, Pia R.-M. Siljander, +57 authors Olivier De Wever
Journal of extracellular vesicles
2015

In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer… (More)

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Abdel Kareem Azab, Jinsong Hu, +15 authors Irene M Ghobrial
Blood
2012

The spread of multiple myeloma (MM) involves (re)circulation into the peripheral blood and (re)entrance or homing of MM cells into new sites of the BM. Hypoxia in solid tumors was shown to promote… (More)

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Leukothea Ioakimidis, Jacob D Soumerai, +12 authors Irene M Ghobrial
Journal of clinical oncology : official journal…
2009

PURPOSE We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). PATIENTS AND METHODS A cycle of… (More)

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Paul G Richardson, Edie Weller, +22 authors Kenneth C. Anderson
Blood
2010

This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3… (More)

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Aldo M Roccaro, Antonio Sacco, +10 authors Irene M Ghobrial
The Journal of clinical investigation
2013

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this… (More)

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Aldo M Roccaro, Antonio Sacco, +13 authors Irene M Ghobrial
Blood
2009

Multilevel genetic characterization of Waldenström macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of… (More)

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

Hai T. Ngo, Xavier Leleu, +12 authors Irene M Ghobrial
Blood
2008

Waldenstrom macroglobulinemia (WM) is characterized by widespread involvement of the bone marrow at the time of diagnosis, implying continuous homing of WM cells into the marrow. The mechanisms by… (More)

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Abdel Kareem Azab, J. Matthew Runnels, +21 authors Irene M Ghobrial
Blood
2009

The interaction of multiple myeloma (MM) cells with their microenvironment in the bone marrow (BM) provides a protective environment and resistance to therapeutic agents. We hypothesized that… (More)

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Yazan Alsayed, H. X. Ngo, +20 authors Irene M Ghobrial
Blood
2007

The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences